(Q44242585)

1 December 2017

title

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia (English)

1 reference

1 December 2017

0 references

1 reference

7

1 reference

1 December 2017

Francesc Bosch

1

0 references

Emili Montserrat

14

object named as

Emili Montserrat

1 reference

1 December 2017

Anna Ferrer

2

1 reference

1 December 2017

Armando López-Guillermo

3

1 reference

1 December 2017

Eva Giné

4

1 reference

1 December 2017

Beatriz Bellosillo

5

1 reference

1 December 2017

Neus Villamor

6

1 reference

1 December 2017

Francesc Cobo

8

1 reference

1 December 2017

María Perales

9

1 reference

1 December 2017

Jordi Esteve

10

1 reference

1 December 2017

Albert Altés

11

1 reference

1 December 2017

Joan Besalduch

12

1 reference

1 December 2017

Josep M Ribera

13

1 reference

1 December 2017

GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears)

15

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

British Journal of Haematology

1 December 2017

language of work

1 reference

1 December 2017

volume

119

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

976-984

1 reference

Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03959.X

10.1046/J.1365-2141.2002.03959.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference